Company intelligence / Profile preview

Lifordi Immunotherapeutics

Burlington, Massachusetts, United Stateslifordi.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lifordi's lead candidate LFD-200 has demonstrated efficacy in multiple preclinical disease models, including a rheumatoid arthritis mouse model. In non-human primates, LFD-200 showed a relatively low serum half-life of 14 hours, but its payload is retained in immune organs for longer periods, supporting reduced systemic toxicity and lower dosing for targeted activity in immune organs.[7]

Therapeutic areas: Immunology
Modalities: Antibody-drug conjugates (ADCs)Antibody Fragment-Drug Conjugates (FDCs)
Industry: Biotech

Drug pipeline

1 asset

LFD-200

Beyond the preview

Go deeper on Lifordi Immunotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lifordi Immunotherapeutics.

Explore the full profile